Loading
Latest filing published 22 Apr 2026 for XSpray Pharma AB (publ), €1.4M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Anders Ekblom on record concern XSpray Pharma AB (publ), in the capacity of board member. The record holds 2 filings, for trades running from 9 September 2025 to 21 April 2026.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 22 April 2026, the filings show a transaction worth €1.4M in XSpray Pharma AB (publ). Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations